ClinicalTrials.gg
RecruitingNCT07860840IVSUpdated Oct 6, 2026

Efficacy of Intensive Visual Simulation (IVS) Before Exoskeleton-assisted Step Training in Patients With Hemisensory Syndrome With Brain Injury of Vascular Etiology.

An interventional study of Rehabilitation treatment with IVS before step training using an exoskeleton and Rehabilitation treatment with step training using an exoskeleton in Exoskeleton Device, Sensory Disorder and Brain Injuries, Vascular, sponsored by IRCCS Sacro Cuore Don Calabria di Negrar. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by IRCCS Sacro Cuore Don Calabria di Negrar · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Apr 2024, registered Sep 2026).
  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Clinical trial involving a medical device, not intended for CE marking, randomized, blinded to evaluate the efficacy of preparatory treatment with Intensive Visual Simulation 4 (IVS) prior to exoskeleton-assisted (EKSO) step training in achieving independent ambulation in hemiparetic patients with impaired proprioceptive sensation. Patients will be randomized into two groups: one group in which patients will undergo IVS treatment before physiotherapy and robotic step training with an exoskeleton; and one group in which patients will undergo only physiotherapy and robotic step training with an exoskeleton.

Read the detailed description

Enrolled patients will be randomized to one of the two rehabilitation treatment arms included in the trial.

  • Arm A: Rehabilitation treatment with IVS before physiotherapy-based and robotic gait training using an exoskeleton.
  • Arm B: Rehabilitation treatment with physiotherapy-based and robotic step training using an exoskeleton.

Training will last:

  • 15 minutes of IVS (only for Arm A)
  • 30 minutes of EKSO training (which in Arm A will be performed after IVS treatment)
  • 45 minutes of non-robotic motor therapy following robotic treatment.

Each rehabilitation session will last a maximum of approximately 1.5 hours and will be repeated 5 days a week for 3 weeks.

Clinical evaluations will be conducted by a physician who is unaware of the rehabilitation treatment the patient has undergone (the patient will be appropriately informed of the need not to disclose the type of rehabilitation received to the evaluating physician).

02

Conditions studied

  • Exoskeleton Device
  • Sensory Disorder
  • Brain Injuries, Vascular

Browse trials for

Keywords

  • EKSO
  • Intensive Visual Simulation
  • Exoskeleton device
  • sensory hemisyndrome
  • Brain Injuries, Vascular
03

In context

Sensation Disorders

87 studies on the registry are indexed under Sensation Disorders; 23 are open to participants now.

This study's planned enrollment of 22 is below the median of 40 across 56 interventional studies indexed under Sensation Disorders.

Browse Sensation Disorders studies →

Lead sponsor

IRCCS Sacro Cuore Don Calabria di Negrar is the lead sponsor of 38 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged 18 to 80 years (both ends included).
  • Diagnosis of hemiparesis/plegia with proprioceptive sensory deficit due to a cerebrovascular event within the last 6 months
  • Orientation in the 3 domains (space, time, and person)
  • Cooperation
  • Clinical stability
  • Trunk control while standing
  • Signature of the Form for participation in the study and for the processing of personal data

Exclusion criteria

Exclusion Criteria:

  • Patients aged \< 18 years and > 80 years
  • Patients who are disoriented in at least one of the three domains (space, time, and person)
  • Non-cooperative patients
  • Patients with global aphasia
  • Patients with severe ideomotor apraxia
  • Patients with cognitive or mental disorders
  • Patients not eligible for EKSO:
  • Severe comorbid conditions: infections, circulatory, cardiac, or pulmonary diseases, pressure ulcers.
  • Severe spasticity (level 4 on the modified Ashworth scale).
  • Spinal instability or unhealed fractures of the limbs or pelvis.
  • Heterotopic ossification.
  • Psychiatric or cognitive conditions that may interfere with the proper use of the device.
  • Pregnant women.
  • Reduced tolerance for standing due to orthostatic hypotension.
  • Range of motion (ROM) limitations that would prevent the patient from achieving a normal bilateral gait pattern or performing normal transitions from a seated to a standing position and vice versa: Bilateral hip flexion less than 110°, knee flexion contracture greater than 12°, or inability to achieve neutral dorsiflexion of 0° with knee flexion up to 12°.
  • Leg length discrepancy greater than 1.27 cm for the upper leg and 1.9 cm for the lower leg.
  • Unresolved deep vein thrombosis.
  • Uncontrolled autonomic dysreflexia.
  • Lower limb prostheses.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Rehabilitation treatment with IVS before step training using an exoskeleton

    Device: Rehabilitation treatment with IVS before step training using an exoskeleton

  • Active comparator
    Rehabilitation treatment with step training using an exoskeleton

    Device: Rehabilitation treatment with step training using an exoskeleton

Interventions

  • DeviceRehabilitation treatment with IVS before step training using an exoskeleton

    * 15 minutes of IVS: The physical therapist will show the patient a pre-recorded sequence of movements and activities involving the lower limb. Patient will observe the movements on a screen positioned to cover the paretic limb and will then be ask to repeat them. * 30 minutes of EKSO training:The physical therapist will set up the training using a single program defined as "assistive" to observe the degree of dependence on the machine throughout the course of treatment and will maintain this setting for all sessions, documenting the percentage changes in the level of assistance required. * 45 minutes of non-robotic motor therapy following the robotic treatment. The physical therapist will perform motor treatments involving mobilization, muscle strengthening, and standing with the goal of improving the patient's ability to perform transfers and maintain an upright position independently. The rehabilitation treatment session will be repeated 5 days a week for 3 weeks.

  • DeviceRehabilitation treatment with step training using an exoskeleton

    * 30 minutes of EKSO training: The physical therapist will set up the training using a single program defined as "assistive" to observe the degree of dependence on the machine throughout the course of treatment and will maintain this setting for all sessions, documenting the percentage changes in the level of assistance required. * 45 minutes of non-robotic motor therapy following the robotic treatment. The physical therapist will perform motor treatments involving mobilization, muscle strengthening, and standing with the goal of improving the patient's ability to perform transfers and maintain an upright position independently. The rehabilitation treatment session will be repeated 5 days a week for 3 weeks.

06

What researchers measure

Primary outcomes

  1. Efficacy of preparatory treatment with Intensive Visual Simulation (IVS) for step training with an exoskeleton (EKSO)

    Scores on the Berg Balance Scale from baseline to the end of treatment. The scale assesses static and minimal dynamic balance, as well as the risk of falling. The score ranges from 0 to 56.

    Time frame: Baseline to Timepoint 1 (3 weeks after)

  2. Efficacy of preparatory treatment with Intensive Visual Simulation (IVS) for step training with an exoskeleton (EKSO)

    Scores on the Timed Up and Go test from baseline to the end of treatment. The test measures, in seconds, the time it takes a patient to stand up from a chair with armrests, walk 3 meters, turn around, walk back, and sit down again.

    Time frame: Baseline to Timepoint 1 (3 weeks after)

Secondary outcomes

  1. Revised Nottingham Sensory Assessment Scale Score

    Revised Nottingham Sensory Assessment Scale Score for evaluating sensitivity in the paretic hemibody

    Time frame: Baseline to Timepoint 2 (7 weeks after)

  2. Range of Motion (ROM) Values for the Tibiotarsal and Knee Joints

    Range of Motion (ROM) Values for Assessment of the Tibiotarsal and Knee Joints

    Time frame: Baseline to Timepoint 2 (7 weeks after)

  3. Presence/absence of tendon retractions

    Presence/absence of tendon retractions in the knee and tibiotarsal flexor-extensor muscles and the tibiotarsal pronator-supinator muscles

    Time frame: Baseline to Timepoint 2 (7 weeks after)

  4. Ashworth Scale (MAS)

    Ashworth Scale (MAS) for Assessing Muscle Tone

    Time frame: Baseline to Timepoint 2 (7 weeks after)

  5. Minimum number of sessions required to achieve independent walking with assistive devices

    Evaluation of the minimum number of sessions required to achieve independent walking with assistive devices.

    Time frame: Baseline to Timepoint 1 (3 weeks after)

  6. Percentage of assistance provided by EKSO

    Percentage of assistance provided by EKSO as recorded by the machine after 10 minutes, after 20 minutes, and at the end of 30 minutes of robotic training.

    Time frame: Baseline to Timepoint 2 (7 weeks after)

  7. Number of steps taken during a training session with EKSO

    Number of steps taken during a single 30-minute training session with EKSO, as recorded by the machine.

    Time frame: Baseline to Timepoint 2 (7 weeks after)

  8. Assessment of the maintenance of skills acquired through preparatory training, with or without Intensive Visual Simulation (IVS), for exoskeleton (EKSO) step training

    Values after 7 weeks from the Timed Up and Go Test. The test measures, in seconds, the time it takes a patient to stand up from a chair with armrests, walk 3 meters, turn around, walk back, and sit down again.

    Time frame: Timepoint 2 (7 weeks after baseline)

  9. Assessment of the maintenance of skills acquired through preparatory training, with or without Intensive Visual Simulation (IVS), for exoskeleton (EKSO) step training

    Values after 7 weeks from the Berg Balance Scale. The scale assesses static and minimal dynamic balance, as well as the risk of falling. The score ranges from 0 to 56.

    Time frame: At Timepoint 2 (7 weeks after baseline)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Sep 2027, 41 months after the start.

Of 32 interventional studies with no phase under Sensation Disorders, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 45. This study's planned 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Oct 6, 2026
StartActual
Apr 21, 2024
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860840
Lead sponsor
IRCCS Sacro Cuore Don Calabria di Negrar
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Apr 21, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Elvia Malo, Dr.
Contact
ricerca.clinica@sacrocuore.it
+39 045.6014877

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion